JUNS

NASDAQ · Pharmaceuticals

Jupiter Neurosciences Inc

Penny Stocks Pharmaceutical Stocks Healthcare Stocks

$2.20

+0.07 (+3.29%)

As of Nov 7, 2:44 AM ET ·

JUNS News4 articles

Jupiter Neurosciences Soars 59% on Massive Volume Spike

Jupiter Neurosciences (JUNS) jumped 59% on massive volume, trading at 58.8x its share count. Yet market cap remains far below Nasdaq's $35M threshold.

Jupiter Neurosciences Stock Retreats After Securing U.S. MDMA Rights

Jupiter Neurosciences shares fell from a 67% rally after securing U.S. rights for a trial-stage MDMA drug, with the stock rising only 6.2% amid concerns over financing and dilution.

Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering

Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.

Oracle Shares Slide 4.4% on Project Jupiter Force Majeure Notice

Oracle shares fell 4.4% after a force majeure notice on Project Jupiter raised delay risks. With $288B in lease commitments and negative free cash flow, investors question execution.